Indication
Adult Acute Myeloid Leukemia With Del(5q)
6 clinical trials
8 products
8 drugs
Clinical trial
A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients With High-Risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2022-09-06
Drug
cyclophosphamideProduct
Anti-thymocyte globulinDrug
tacrolimusDrug
methotrexateClinical trial
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2028-04-19
Product
SirolimusProduct
AzacitidineClinical trial
Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Advanced Myeloid MalignanciesStatus: Terminated, Estimated PCD: 2011-05-17
Drug
busulfanDrug
etoposideClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2018-03-06
Product
MitoxantroneDrug
etoposideDrug
cytarabineProduct
selinexorClinical trial
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous LeukemiaStatus: Completed, Estimated PCD: 2019-12-12
Drug
sirolimusProduct
IdarubicinProduct
Cytarabine